PPLPHARMA
Piramal Pharma
Each stock's 10,000-path forecast, rendered as light.
Piramal Pharma (PPLPHARMA) Stock Analysis & Case Study
Is PPLPHARMA a good buy? The data-driven verdict.
Piramal Pharma (PPLPHARMA) trades at ₹159,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 24/100.
On the numbers, Piramal Pharma (PPLPHARMA) high-risk on the numbers, a Downstox Snapshot Score of 24/100, weighing expensive at 61.4× earnings, ROE of -3.6%, a 43% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
PPLPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is PPLPHARMA overvalued? PPLPHARMA P/E vs its sector
PPLPHARMA's P/E of 61.4× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.09% dividend yield is below the peer median of 1.65%.
PPLPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of PPLPHARMA history (1%/yr drift, 41%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| PPLPHARMA 2027 | ₹87 | ₹147 | ₹247 | -7% |
| PPLPHARMA 2028 | ₹65 | ₹136 | ₹283 | -14% |
| PPLPHARMA 2029 | ₹51 | ₹126 | ₹311 | -21% |
| PPLPHARMA 2030 | ₹40 | ₹116 | ₹331 | -27% |
| PPLPHARMA 2031 | ₹33 | ₹108 | ₹346 | -32% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability PPLPHARMA goes up, or doubles?
The bull case for PPLPHARMA
- Piramal Pharma is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹311.
The bear case & risks
- A rich 61.4× P/E leaves a thin margin of safety if growth slows.
- A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.
- The probability model is cautious 12 months out, only a 43% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹51.
PPLPHARMA volatility & expected range, how bumpy is the ride?
Over the last 2.0 years PPLPHARMA compounded at 1%/year with annualized volatility of 41%. That volatility implies a 1-year 80% range of ₹87–₹247, the honest backbone behind any single price target.
PPLPHARMA price forecast, the full 60-month probability fan
PPLPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds PPLPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the PPLPHARMA price target & forecast page.
PPLPHARMA Piotroski F-Score: 3/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. PPLPHARMA scores 3/9,weak on the financial-strength checks.
PPLPHARMA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy PPLPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 32.3% | 3.1× |
| ZerodhaCHEAPEST | 32.3% | 3.1× |
| DhanCHEAPEST | 32.3% | 3.1× |
Compare every broker on the PPLPHARMA MTF page.
PPLPHARMA vs peers,sector comparison
About Piramal Pharma: sector, index & market-cap context
Piramal Pharma (PPLPHARMA) is a mid-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹21,116 Cr. See more Nifty 200 stocks.
How the PPLPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Piramal Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PPLPHARMA analysis, FAQs
Is Piramal Pharma (PPLPHARMA) a good buy?
On the numbers, Piramal Pharma (PPLPHARMA) high-risk on the numbers, a Downstox Snapshot Score of 24/100, weighing expensive at 61.4× earnings, ROE of -3.6%, a 43% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is PPLPHARMA overvalued or undervalued?
PPLPHARMA trades at 61.4× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the PPLPHARMA share price target for 2031?
PPLPHARMA's probability-weighted 2031 median target is ₹108, with an 80% range of ₹33–₹346 (10,000-path Monte-Carlo).
What is the probability PPLPHARMA doubles in 5 years?
The modelled probability of PPLPHARMA reaching ₹318 (2×) within 5 years is 11%.
What is the bull case for PPLPHARMA?
Piramal Pharma is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in PPLPHARMA?
A rich 61.4× P/E leaves a thin margin of safety if growth slows. A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing. The probability model is cautious 12 months out, only a 43% chance of finishing above today's price.